跳至主要内容
临床试验/NL-OMON50612
NL-OMON50612已完成3 期

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction - 20110203 - GALACTIC HF

Amgen0 个研究点目标入组 180 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Amgen
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • •- Subject has provided informed consent
  • •- Male or female, * 18 to * 85 years of age
  • •- History of chronic HF
  • •- LVEF * 35%
  • •- NYHA class II to IV
  • •- Managed with HF SoC therapies consistent with regional clinical practice
  • •- Current hospitalization with primary reason of HF or prior HF
  • •hospitalization, or urgent HF admission to emergency department (ED) within 1
  • •year prior to screening
  • •- BNP level * 125 pg/mL or an NT-proBNP level * 400 pg/mL at most recent
  • •screening assessment (for subjects with atrial fibrillation, the cut off levels
  • •are: BNP * 375 pg/mL or NT proBNP * 1200 pg/mL)

排除标准

  • •- Inability to swallow study medication tablet
  • •- Receiving mechanical hemodynamic support or mechanical ventilation * 7 days
  • •prior to randomization
  • •- Receiving IV inotropes or IV vasopressors * 3 days prior to randomization
  • •- Receiving IV diuretics or IV vasodilators, or supplemental oxygen therapy *
  • •12 hours prior to randomization
  • •- Acute coronary syndrome, stroke, or transient ischemic attack, major cardiac
  • •surgery, percutaneous coronary intervention, or valvuloplasty within the 3
  • •months prior to randomization
  • •- Severe uncorrected valvular heart disease, or hypertrophic obstructive
  • •cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically
  • •significant congenital heart disease
  • •- Routinely scheduled outpatient intravenous infusions for HF (eg, inotropes,
  • •vasodilators, diuretics) or routinely scheduled ultrafiltration
  • •- Systolic blood pressure > 140 mmHg or < 85 mmHg, or diastolic blood pressure
  • •> 90 mmHg, or heart rate > 110 beats per minute, or < 50 beats per minute at
  • •- Estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2

研究者

发起方
Amgen

相似试验

进行中(未招募)
1 期
Multicenter Exercise Tolerance Evaluation of Omecamtiv mecarbil Related to Increased Contractility in Heart Failure (METEORIC-HF)Chronic Heart Failure with Reduced Ejection FractionMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849
EUCTR2018-001233-40-FRAmgen Inc270
进行中(未招募)
不适用
A research study to find out if people with Primary Generalized Tonic-Clonic Seizures, by taking perampanel in addition to their normal epilepsy medicine(s), have fewer seizures and feel better. Either perampanel (real medicine) or placebo (pretend medicine that looks the same as the real medicine) will be given in addition to ordinary epilepsy medicines. Who gets which is decided randomly. There is an option to continue into the Follow-on (Extension) Phase of the study.Primary Generalized Tonic-Clonic SeizuresMedDRA version: 17.0Level: HLTClassification code 10018101Term: Generalised tonic-clonic seizuresSystem Organ Class: 100000004852
EUCTR2011-000265-12-PLEisai Limited164
进行中(未招募)
1 期
A Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when Evolocumab (AMG 145) is used in combination With Statin Therapy In Patients with Clinically Evident Cardiovascular DiseaseMedDRA version: 18.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861Dyslipidemia
EUCTR2012-001398-97-SKAmgen Inc27,564
进行中(未招募)
1 期
A study investigating the use of Omecamtiv Mecarbil on subjects with heart failureChronic Heart Failure With Reduced Ejection FractionMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849
EUCTR2016-002299-28-SEAmgen Inc8,285
进行中(未招募)
1 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeMedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersDyslipidemia
EUCTR2018-004565-14-SEAmgen Inc.12,000